Rotigotine transdermal system for the management of motor function and sleep disturbances in Parkinson's disease: Results from a 1-year, open-label extension of the RECOVER study

► Rotigotine is a non-ergoline dopamine agonist with activity across D1-D5 receptors. ► Rotigotine is administered once-daily via a transdermal patch for treatment of PD. ► A 1-year open label extension study of RECOVER, the rotigotine Phase IIIb trial. ► Adverse events were mild or moderate in intensity and resolved by trial end. ► Rotigotine had beneficial effects on motor function and sleep for up to 1 year.